AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06549257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25-IMX313, Pfs48/45
Description: Two soluble protein vaccines.
Study NCT05961033 — intervention group
Intervention type: DEVICE
Intervention: Virtual Reality based exercises
Description: Play VR games
Study NCT00911131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy (PillCam ESO)
Description: The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
Study NCT00911131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EGD
Description: Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
Study NCT00911131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy (PillCam ESO) with abdominal binder
Description: An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
Study NCT06518434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: Medical cannabis oil three times daily
Study NCT05282953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIO-301
Description: KIO-301 intravitreal injection at ascending doses
Study NCT06712992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-spinal Direct Current Stimulation
Description: Physiomed- IONOSON-Expert, Germany will be used to deliver SHAM direct current, The Physiomed- IONOSON-Expert, Germany is Two-channel electrotherapy including 21 currents, including direct current. The tsDCS electrodes will be rectangular pieces of saline-soaked synthetic sponge (7 × 8 cm, 56 cm2), to minimize chemical reactions at the electrode-skin interface. The anode will be placed over the spinous process of the eighth thoracic vertebra (T8) and the cathode will be placed on the second lumbar vertebra (L2) according to a modeling study which demonstrated that this configuration had a relevant impact on the distribution of the induced electric field (EF) in the lumbosacral spinal cord for the efficacy of tsDCS.
Study NCT03977311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)
Description: -To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
Study NCT03977311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of Care
Study NCT06712992 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Exercises
Description: 1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine
Study NCT06712992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercises
Description: 1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine
Study NCT06712992 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SHAM Trans-spinal Direct current stimulation
Description: For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs .
Study NCT04891393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Starbucks brand Via instant coffee. (Caffeine Content: 3 mg / kg)
Study NCT04891393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated coffee
Description: Starbucks brand Via instant decaffeinated coffee. (Caffeine Content: 15 - 25 mg)
Study NCT05633303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Substrate guided ablation
Description: Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
Study NCT06505772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine ) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~For example, it begins with an infusion of 4 ml over 10 minutes and then continues the infusion, depending on the weight of the child, at a rate of 1.6 ml/kg/hour.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is.
Study NCT06505772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (NS) for intravenous infusion is supplied in pre-filled syringes of 20 ml, 50 ml, and 100 ml. To maintain blinding in this study, NS is handled identically to the study drug, dexmedetomidine. A physician not involved in the study prepares all injections, randomly assigning either NS or dexmedetomidine using a sealed envelope technique. Prepared syringes are then placed in identical, unmarked infusion pumps.~Infusion Protocol:~Anesthesiologists, blinded to the infusion contents, administer the solutions according to the protocol:~For example,Initial Bolus: 4 ml infused over 10 minutes, Maintenance Infusion: Continued at a rate of 1.6 ml/kg/hour, adjusted to the individual patient's weight.~This process ensures both patient and anesthesiologist remain blinded to the treatment arm, minimizing potential bias throughout the study.
Study NCT05883241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
Study NCT05883241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% Diclofenac Patches
Description: Topical pain relief-gel worn during treatment via SAM patch.
Study NCT05303402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHH1-V
Description: COVID-19 Vaccine HIPRA, 40 mcg/dose
Study NCT06329284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ELISA
Description: ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
Study NCT05323058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tulsi extract
Description: 4% topical oral spray
Study NCT05323058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzydamine Hydrochloride
Description: 0.15% topical oral spray
Study NCT04788368 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection with either of the above mentioned techniques
Study NCT05194371 — intervention group
Intervention type: RADIATION
Intervention: definitive radiotherapy or definitive chemoradiotherapy
Description: A total dose of radiation therapy should be more than 50Gy
Study NCT06230601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cough Trick Method
Description: During the Blood Collection Procedure in School-Age Children, one group will use the Cough Trick Method
Study NCT06230601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pinwheel Blowing method
Description: Pinwheel Blowing method
Study NCT04825470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Liver Transplantation
Study NCT06313788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Possession of a customized placebo analgesic band-aid prior to vaccination or injection
Description: Participants will be told that in order to thank them for doing the marketing interview, as a token of appreciation, they will receive a free band-aid with a customized cartoon of their preference. They will be displayed band-aids with different cartoon images (such as Luffy, minions etc) from which they can freely choose their favorite one . They will be asked to sign their name on the band-aid. This is to establish their sense of ownership. Lastly, with the assistance of the parent, they will be encouraged to anticipate and describe how the owned band-aid is important to them and can help them cope with the forthcoming pain from injection.
Study NCT06739252 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gemcitabine Oxaliplatin and 5FU
Description: The perioperative treatment plan includes neoadjuvant therapy and adjuvant therapy. Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance treatment for three cycles. The total treatment duration for the perioperative period is six months. HAIC regimen: gemcitabine (1,000 mg/m2, 2h, d1) + oxaliplatin (35 mg/m2, 2h, d1-2) + 5-FU (0.75g/m2, 22h, d1-2); atezolizumab (PD-L1 inhibitor): 1200 mg, intravenous infusion, administered within 24 hours before HAIC treatment; bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment (bevacizumab use is paused during the third neoadjuvant treatment). Each cycle lasts for three weeks.
Study NCT06734351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOA VOLUME
Description: Subcutaneous and/or Supraperiosteal Plane Injection
Study NCT06734351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLUMA XC
Description: Subcutaneous and/or Supraperiosteal Plane Injection
Study NCT06153004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP)
Description: HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
Study NCT06153004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
Study NCT05724693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: Day 1: A single dose of BEM will be administered
Study NCT05178368 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical/ Transcatheter aortic valve replacement
Description: The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
Study NCT05326854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supportive care
Description: After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
Study NCT06437444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The implementation strategy to encourage the adoption of the Care Pathway
Description: 1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Audit \& Feedback (A\&F) data reports, sent every two weeks, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~3. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~4. Distribution of reminder posters in paediatrics consultations, PEDs and health centers.
Study NCT04865367 — intervention group
Intervention type: OTHER
Intervention: Exposure to culture media
Description: Exposure to culture media
Study NCT04873479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
Study NCT04873479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: saline
Description: Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
Study NCT06182592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal cytarabine-daunorubicin for injection
Description: First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
Study NCT06182592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7+3 (cytarabine and daunorubicin)
Description: First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.
Study NCT05849870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frailty care pathway for older people in a rural primary care setting
Description: This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
Study NCT05849870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty care pathway for older people in a rural primary care setting
Description: This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
Study NCT06774833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-initiated perturbation-based balance training
Description: This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be required to recover their balance upon self-initiated perturbation.
Study NCT06774833 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balance training
Description: This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be instructed to perform balance and strength training. The same training duration and format will be used as the Self-initiated perturbation-based balance training group.
Study NCT06774040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etribnabdione 25 mg BID
Description: The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.
Study NCT06774040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etribnabdione 50 mg BID
Description: The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.
Study NCT05501600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
Study NCT05501600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
Study NCT01120119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT01120119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitriol
Study NCT05029063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban 10 MG
Description: Identical comparator drug
Study NCT05029063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Identical comparator drug
Study NCT06000358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic cryotherapy
Description: The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.
Study NCT06000358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: As a standard of care, patients will receive pembrolizumab.
Study NCT06000358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapy
Description: As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.
Study NCT06773338 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tetris
Description: Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
Study NCT06773338 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Participants do not receive any intervention.
Study NCT06770816 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: HR, MAP, SBP and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Changes in LV systolic function will be assessed with three parameters: fractional shortening (FS), ejection fraction (EF) using the Simpson method and S' wave of tissue Doppler imaging (TDI) of the mitral annulus (average of values at the medial and lateral annulus). LV diastolic function will be assessed with three parameters and interpreted according to the European Association of Cardiovascular Imaging guidelines. Pulsed wave (PW) Doppler of trans-mitral flow will be used to obtain the ratio between early (e) and late (atrial, a) waves. A PW Doppler between the LV outflow tract and the mitral valve will be performed to estimate the iso-volumetric relaxation time IVRT. TDI will be used to investigate myocardial relaxation at the mitral annular level (ear
Study NCT05680532 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black raspberry
Description: Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.
Study NCT05680532 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
Study NCT05919602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualization of an image catalogue
Description: Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.